[go: up one dir, main page]

CY2014041I1 - 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια - Google Patents

2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια

Info

Publication number
CY2014041I1
CY2014041I1 CY2014041C CY2014041C CY2014041I1 CY 2014041 I1 CY2014041 I1 CY 2014041I1 CY 2014041 C CY2014041 C CY 2014041C CY 2014041 C CY2014041 C CY 2014041C CY 2014041 I1 CY2014041 I1 CY 2014041I1
Authority
CY
Cyprus
Prior art keywords
nitroimidazo
oxazole
dihydro
Prior art date
Application number
CY2014041C
Other languages
English (en)
Other versions
CY2014041I2 (el
Original Assignee
Otsuka Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co., Ltd filed Critical Otsuka Pharmaceutical Co., Ltd
Publication of CY2014041I1 publication Critical patent/CY2014041I1/el
Publication of CY2014041I2 publication Critical patent/CY2014041I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CY2014041C 2002-10-11 2014-09-24 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια CY2014041I2 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002298259 2002-10-11
PCT/JP2003/013070 WO2004033463A1 (ja) 2002-10-11 2003-10-10 ２，３−ジヒドロ−６−ニトロイミダゾ[２，１−ｂ]オキサゾール化合物

Publications (2)

Publication Number Publication Date
CY2014041I1 true CY2014041I1 (el) 2016-07-27
CY2014041I2 CY2014041I2 (el) 2016-07-27

Family

ID=32089299

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20131100076T CY1113578T1 (el) 2002-10-11 2013-01-25 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
CY2014041C CY2014041I2 (el) 2002-10-11 2014-09-24 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20131100076T CY1113578T1 (el) 2002-10-11 2013-01-25 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια

Country Status (26)

Country Link
US (1) US7262212B2 (el)
EP (2) EP1555267B1 (el)
JP (1) JP4186065B2 (el)
KR (1) KR100723847B1 (el)
CN (4) CN102532162B (el)
AR (4) AR041198A1 (el)
AU (1) AU2003272979B2 (el)
BE (1) BE2014C053I2 (el)
BR (1) BRPI0314344B8 (el)
CA (1) CA2497569C (el)
CY (2) CY1113578T1 (el)
DK (1) DK1555267T3 (el)
ES (1) ES2400179T3 (el)
FR (1) FR14C0066I2 (el)
HU (1) HUS1400046I1 (el)
LU (1) LU92517I2 (el)
MX (1) MXPA05003674A (el)
MY (1) MY139244A (el)
PL (3) PL217919B1 (el)
PT (1) PT1555267E (el)
RU (1) RU2326121C3 (el)
SI (1) SI1555267T1 (el)
TW (1) TWI347946B (el)
UA (1) UA83200C2 (el)
WO (1) WO2004033463A1 (el)
ZA (1) ZA200501033B (el)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
KR100655670B1 (ko) * 2002-10-15 2007-02-28 오쓰까 세이야꾸 가부시키가이샤 1-치환된 4-니트로이미다졸 화합물 및 이의 제조 방법
BRPI0414909A (pt) * 2003-10-31 2006-11-07 Otsuka Pharma Co Ltd composto, agente antituberculoso, e, método para produzir um composto
JP4761756B2 (ja) * 2003-10-31 2011-08-31 大塚製薬株式会社 ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物
TWI300409B (en) 2004-02-18 2008-09-01 Otsuka Pharma Co Ltd Method for producing 4-nitroimidazole compound
BRPI0509292B1 (pt) 2004-03-31 2015-06-23 Nippon Soda Co Composto de amina cíclica e composição
JP4789966B2 (ja) * 2004-04-09 2011-10-12 大塚製薬株式会社 医薬組成物
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
ATE450525T1 (de) * 2005-06-20 2009-12-15 Schering Corp Kohlenstoffgebundene substituierte piperidine und derivate daraus als histamin-h3-antagonisten
WO2007013477A1 (en) * 2005-07-28 2007-02-01 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical composition comprising 2 , 3-dihydro-6-nitroimidazo [2 , 1-b] oxazole derivatives
JP5105818B2 (ja) * 2005-10-05 2012-12-26 大塚製薬株式会社 医薬組成物
TW201233389A (en) * 2005-10-05 2012-08-16 Otsuka Pharma Co Ltd Antituberculous therapeutic drugs and kit containing the same
BRPI0616667B1 (pt) * 2005-10-06 2017-07-18 Nippon Soda Co. , Ltd. Compounds of cyclical amine or salts thereof or non-oxides thereof, and agents for control of fever
TW200800268A (en) * 2005-11-04 2008-01-01 Otsuka Pharma Co Ltd Medicinal composition showing improved drug absorbability
WO2007078335A2 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
CA2640304A1 (en) * 2006-02-13 2007-08-23 Laboratoires Serono S.A. Sulfonamide derivatives for the treatment of bacterial infections
JP2007297305A (ja) * 2006-04-28 2007-11-15 Daiso Co Ltd Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法
US8835426B2 (en) * 2007-02-26 2014-09-16 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1
AR070301A1 (es) 2007-05-08 2010-03-31 Otsuka Pharma Co Ltd Compuesto epoxi y metodo para producir el mismo
CL2008002199A1 (es) * 2007-07-26 2009-10-23 Vitae Pharmaceuticals Inc Compuestos derivados de 1,3-oxazin-2-ona; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad asociada con la actividad de la 11beta-hidroxiesteroide deshidrogenasa tipo 1 (11beta-hsd1) tales como dislipidemia, hiperlipidemia, hipertension, obesidad y enfermedad cardiovascular, entre otras.
EP2185542A2 (en) * 2007-08-15 2010-05-19 Glaxo Group Limited Substituted quinoline derivatives as h1 receptor antagonists
JP2011500634A (ja) * 2007-10-16 2011-01-06 グラクソ グループ リミテッド 炎症性疾患およびアレルギー性疾患の治療に用いるキノリン誘導体
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
US8592409B2 (en) 2008-01-24 2013-11-26 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11β-hydroxysteroid dehydrogenase 1
EP2252598A2 (en) * 2008-02-11 2010-11-24 Vitae Pharmaceuticals, Inc. 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2715290A1 (en) * 2008-02-15 2009-08-20 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2009117109A1 (en) * 2008-03-18 2009-09-24 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
CA2712613C (en) * 2008-03-26 2017-02-28 Global Alliance For Tb Drug Development Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones
EP2291371B1 (en) 2008-05-01 2015-06-10 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8242111B2 (en) * 2008-05-01 2012-08-14 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
JP5538365B2 (ja) 2008-05-01 2014-07-02 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
TW200946520A (en) * 2008-05-01 2009-11-16 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2324017B1 (en) 2008-07-25 2014-12-31 Boehringer Ingelheim International GmbH INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1
WO2010127237A2 (en) * 2009-04-30 2010-11-04 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CN104327062A (zh) 2008-07-25 2015-02-04 贝林格尔·英格海姆国际有限公司 11β-羟基类固醇脱氢酶1的环状抑制剂
AU2009283195A1 (en) * 2008-08-18 2010-02-25 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
WO2010143007A1 (en) * 2009-06-10 2010-12-16 Dynamit Nobel Gmbh Explosivstoff-Und Systemtechnik Method for the production of 2-halogeno-4-nitroimidazole
US8558005B2 (en) * 2008-08-21 2013-10-15 Dynamit Nobel Gmbh Explosivstoff-Und Systemtechnik Methods for the production of 2-halo-4-nitroimidazole and intermediates thereof
US8637505B2 (en) 2009-02-04 2014-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
KR101746482B1 (ko) * 2009-07-31 2017-06-27 글로벌 알리앙스 포 티비 드럭 디벨롭먼트 니트로이미다조옥사진 및 항결핵 치료요법에서의 이의 용도
CA2769263C (en) * 2009-07-31 2017-03-07 Global Alliance For Tb Drug Development Nitroimidazooxazine and nitroimidazooxazole analogues and their uses
US9198913B2 (en) 2009-07-31 2015-12-01 Global Alliance For Tb Drug Development Nitroimidazooxazines and their uses in anti-tubercular therapy
US20120219500A1 (en) 2009-10-26 2012-08-30 Fujifilm Ri Pharma Co., Ltd. Diagnostic agent for infectious diseases
TW201200523A (en) 2010-01-29 2012-01-01 Otsuka Pharma Co Ltd Synthetic intermediate of oxazole compound and method for producing the same
GB201012209D0 (en) * 2010-05-31 2010-09-08 Ge Healthcare Ltd In vivo imaging agent
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
EP2585444B1 (en) 2010-06-25 2014-10-22 Boehringer Ingelheim International GmbH Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
CA2813671A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
WO2012141338A1 (en) 2011-04-15 2012-10-18 Otsuka Pharmaceutical Co., Ltd. 6,7 - dihydroimidazo [2, 1 - b] [1, 3] oxazine bactericides
JP2015006994A (ja) * 2011-10-28 2015-01-15 大正製薬株式会社 ジヒドロイミダゾオキサゾール誘導体
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
FR3000064A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
EP3052503B1 (en) * 2013-10-04 2018-10-24 Council of Scientific & Industrial Research 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles and a process for the preparation thereof
CN103524492A (zh) * 2013-10-23 2014-01-22 中国药科大学 侧链含硝基咪唑基团取代的喹诺酮类化合物、其制备及用途
TWI687409B (zh) 2014-08-28 2020-03-11 日商大塚製藥股份有限公司 稠合雜環化合物
WO2016063298A1 (en) * 2014-10-21 2016-04-28 Council Of Scientific & Industrial Research Substituted 1,2,3-triazol-1-yl-methyl-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazoles as anti-mycobacterial agents and a process for the preparation thereof
CN105732659B (zh) * 2014-12-12 2019-07-16 上海阳帆医药科技有限公司 硝基咪唑类化合物及其制备方法和在制药中的用途
CN107207532B (zh) * 2015-01-29 2019-07-30 南京明德新药研发股份有限公司 抗肺结核病的硝基咪唑衍生物
JP6776226B2 (ja) * 2015-03-27 2020-10-28 大塚製薬株式会社 １−（４−ヒドロキシフェニル）−４−（４−トリフルオロメトキシフェノキシ）ピペリジン又はその塩の製造方法
CN106317072B (zh) * 2015-06-17 2020-03-17 盟科医药技术(上海)有限公司 用于分枝杆菌感染治疗的杂环化合物及其应用
WO2017146246A1 (ja) 2016-02-26 2017-08-31 大塚製薬株式会社 ピペリジン誘導体
CN105859628B (zh) * 2016-04-19 2018-08-07 清远职业技术学院 一种抗菌化合物对n咪唑苯甲醛缩邻甲苯胺希夫碱及其制备方法和应用
JP2019521175A (ja) * 2016-07-22 2019-07-25 メッドシャイン ディスカバリー インコーポレイテッド ニトロイミダゾール系化合物の結晶形、塩形およびその製造方法
US11254689B2 (en) * 2017-08-16 2022-02-22 Glaxosmithkline Intellectual Property Development Limited Compounds
GEP20257802B (en) 2018-06-11 2025-09-25 Otsuka Pharma Co Ltd Delamanid-containing composition
CN109705022A (zh) * 2018-12-28 2019-05-03 上海彩迩文生化科技有限公司 一种芳香胺中间体的制备方法
CN112300192B (zh) * 2019-08-02 2023-08-11 南京长澳医药科技有限公司 硝基咪唑类化合物及其制备方法和用途
CN110483549B (zh) * 2019-08-30 2021-03-05 沈阳药科大学 一种硝基咪唑吡喃类抗结核药物的制备方法
CN110615800A (zh) * 2019-10-16 2019-12-27 李丽丽 硝基咪唑类化合物及其制备方法和用途
CN112156088B (zh) * 2020-10-30 2021-08-31 健民药业集团股份有限公司 一种化合物在制备结核分枝杆菌抑制剂中的用途
CN113603706A (zh) * 2021-08-04 2021-11-05 深圳市泰力生物医药有限公司 德拉马尼的晶型、含有该晶型的活性药物和药物组合物
EP4563147A1 (en) 2022-07-29 2025-06-04 Otsuka Pharmaceutical Co., Ltd. Delamanid-containing solid dispersion
CN115368252B (zh) * 2022-09-19 2024-01-12 西北农林科技大学 一种4-胺基酚类衍生物及应用
CN116640106B (zh) * 2023-05-11 2024-03-08 郑州大学 一种苯基哌嗪类化合物及其制备方法、应用
CN119059990B (zh) * 2024-11-01 2025-02-07 安徽昊帆生物有限公司 1-氨基甲酸叔丁酯哌嗪的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof

Also Published As

Publication number Publication date
CA2497569A1 (en) 2004-04-22
BRPI0314344B8 (pt) 2021-05-25
KR100723847B1 (ko) 2007-05-31
RU2005114017A (ru) 2006-01-20
MY139244A (en) 2009-09-30
BR0314344A (pt) 2005-07-12
MXPA05003674A (es) 2005-06-08
RU2326121C3 (ru) 2021-09-17
CN101172981A (zh) 2008-05-07
ZA200501033B (en) 2006-06-28
AR089950A2 (es) 2014-10-01
PL217919B1 (pl) 2014-09-30
EP1555267A4 (en) 2010-08-18
SI1555267T1 (sl) 2013-05-31
CY1113578T1 (el) 2016-06-22
US7262212B2 (en) 2007-08-28
CN1705670A (zh) 2005-12-07
FR14C0066I1 (el) 2014-10-17
EP2570418A2 (en) 2013-03-20
HK1171018A1 (en) 2013-03-15
CA2497569C (en) 2011-05-24
EP1555267B1 (en) 2013-01-16
LU92517I2 (fr) 2014-10-13
CN100366624C (zh) 2008-02-06
CN102532162A (zh) 2012-07-04
PT1555267E (pt) 2013-01-29
HUS1400046I1 (hu) 2017-04-28
AR086485A2 (es) 2013-12-18
WO2004033463A1 (ja) 2004-04-22
CN101255170A (zh) 2008-09-03
JP4186065B2 (ja) 2008-11-26
US20060094767A1 (en) 2006-05-04
PL409525A1 (pl) 2014-11-10
KR20050061473A (ko) 2005-06-22
AR041198A1 (es) 2005-05-04
RU2326121C2 (ru) 2008-06-10
TW200420568A (en) 2004-10-16
AU2003272979A1 (en) 2004-05-04
AR091771A2 (es) 2015-02-25
AU2003272979B2 (en) 2009-07-23
BE2014C053I2 (el) 2022-08-30
UA83200C2 (en) 2008-06-25
BRPI0314344B1 (pt) 2019-11-26
EP1555267A1 (en) 2005-07-20
FR14C0066I2 (fr) 2015-05-22
PL376157A1 (en) 2005-12-27
PL404913A1 (pl) 2013-09-30
JP2004149527A (ja) 2004-05-27
ES2400179T3 (es) 2013-04-08
HK1085463A1 (zh) 2006-08-25
CY2014041I2 (el) 2016-07-27
TWI347946B (en) 2011-09-01
EP2570418A3 (en) 2013-07-03
CN102532162B (zh) 2015-05-27
DK1555267T3 (da) 2013-02-11

Similar Documents

Publication Publication Date Title
CY2014041I2 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
DK2308855T3 (da) 2,4-Diaminopyrimidinderivater
DE602004006169D1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate
ATE402152T1 (de) Hiv-inhibierende1,2,4-triazine
NO20053248D0 (no) Kerosenblanding.
DE60305332D1 (de) IMIDAZOi1,2-AöPYRIDINE
NO20052248D0 (no) Svivelstykkesystem.
DE60315471D1 (de) 2,5-disubstituierte 3-mercaptopentansaure
DK1487778T3 (da) Substituerede 4 aminocyclohexanoler
FI20020881A0 (fi) Iskulaite
NO20051500D0 (no) Substituerte heterocyklylpyrimidiner.
ITMI20032170A1 (it) Tagliacimosse.
NO20051497D0 (no) Beta-laktamaseinhibitorprodrug.
NO20044405L (no) Neurotensinaktive 2,3-diaryl-pyrazolidin derivater
ITMI20030916A1 (it) Lancetta.
FI20021381L (fi) Kaivo
AT5889U3 (de) Brennholzspleisser
ES1052590Y (es) Quiosco-consigna.
SE0301847D0 (sv) Novel 3,3-Diphenylpropylamines
ES1052938Y (es) Cantonera.
ES1052945Y (es) Contraventana.
ES1051110Y (es) Caja-palet.
ES1051605Y (es) Cromo-puzzle.
ES1051703Y (es) Potera.
ES1052011Y (es) Espetero.